iAMP® COVID-19 Detection Kit

REF iAMP-COVID19-100
Instructions For Use

Rx Only

For use under an Emergency Use Authorization (EUA) only

IVD For In Vitro Diagnostic Use

V1.0
March, 2020
# Table of Contents

SYMBOLS ........................................................................................................................................... 2
INTENDED USE ....................................................................................................................................... 3
SUMMARY AND EXPLANATION OF THE TEST ....................................................................................... 3
TEST WORKFLOW OVERVIEW .................................................................................................................. 4
KIT COMPONENTS (100 Reactions) ........................................................................................................... 4
EQUIPMENTS & MATERIALS REQUIRED BUT NOT SUPPLIED with the kit ........................................... 5
KIT STORAGE INFORMATION .................................................................................................................. 5
SPECIMENS ............................................................................................................................................. 5
  Biosafety Precautions .......................................................................................................................... 5
  Acceptable Specimens ......................................................................................................................... 5
  Specimen Handling and Storage ......................................................................................................... 6
  Specimen Rejection criteria ............................................................................................................... 6
QUALITY CONTROL ................................................................................................................................. 7
  General Considerations ...................................................................................................................... 7
  Assay Controls .................................................................................................................................. 7
TEST PROCEDURE ..................................................................................................................................... 7
  Specimen Processing .......................................................................................................................... 7
  Reaction assembly: ............................................................................................................................. 8
  Run setup using Biorad CFX96 Manager Software (3.0 or higher) connected to the Biorad CFX96 Real-Time PCR System: .............................................................................................................. 8
AMPLIFICATION RESULT INTERPRETATION ......................................................................................... 9
  iAMP COVID-19 Detection Kit Controls – Positive, Negative ............................................................. 9
  Examination and Interpretation of Patient Specimen Results ............................................................... 10
PERFORMANCE CHARACTERISTICS .................................................................................................... 12
  Limit of Detection (LoD) – Analytical Sensitivity .............................................................................. 12
  Inclusivity ......................................................................................................................................... 13
  Cross-reactivity (Analytical Specificity) .............................................................................................. 13
  Endogenous Interference Substances Studies: ..................................................................................... 15
  Clinical evaluation ............................................................................................................................. 16
IMPORTANT NOTICE
The instruction for use must be read carefully prior to use and followed accordingly. Reliability of results cannot be guaranteed if there are any deviations from these instructions.

SYMBOLS

- Consult instructions for use
- In vitro diagnostic medical device
- Temperature limitation
- Sufficient for <n> tests
- Use by
- Catalogue number
- Batch code

Buffer Mix
Primer Mix
Negative control
Positive control
6X Sample Buffer A
30X Sample Buffer B
Manufacturer
INTENDED USE

The iAMP COVID-19 Detection Kit is a real-time fluorescent reverse transcription isothermal assay intended for the qualitative detection of nucleic acid from the SARS-CoV-2 in nasal, nasopharyngeal (NP), and oropharyngeal (OP) swabs from patients suspected of COVID-19 by their health care provider. Testing is limited to laboratories certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA), 42 U.S.C. §263a, to perform high complexity tests.

Results are for the identification of SARS-CoV-2 RNA. The SARS-CoV-2 RNA is generally detectable in upper respiratory specimens during the acute phase of infection. Positive results are indicative of the presence of SARS-CoV-2 RNA; clinical correlation with patient history and other diagnostic information is necessary to determine patient infection status. Positive results do not rule out bacterial infection or co-infection with other viruses. Laboratories within the United States and its territories are required to report all positive results to the appropriate public health authorities.

Negative results do not preclude SARS-CoV-2 infection and should not be used as the sole basis for patient management decisions. Negative results must be combined with clinical observations, patient history, and epidemiological information.

The iAMP COVID-19 Detection Kit is intended for use by qualified and trained clinical laboratory personnel specifically instructed and trained in the techniques of real-time nucleic acid amplification and in vitro diagnostic procedures. The iAMP COVID-19 Detection Kit is only for use under the Food and Drug Administration’s Emergency Use Authorization.

SUMMARY AND EXPLANATION OF THE TEST

The iAMP COVID-19 Detection Kit is a real-time reverse transcription isothermal amplification test. The test is based on a proprietary isothermal amplification technology termed OMEGA amplification (Patent: WO 2017/205510 A1; publication: The Journal of Molecular Diagnostics, Vol.22, No 3, 419-428, 2020). OMEGA primer sets are designed to specifically detect RNA and later cDNA from the N and ORF-1ab genes of the SARS-CoV-2 virus in nasal, nasopharyngeal and/or oropharyngeal swabs from patients with signs and symptoms of infection who are suspected of COVID-19.

The iAMP COVID-19 assay’s key differentiator from current rRT-PCR COVID-19 assays is its ability to detect SARS-CoV-2 RNA directly from samples without prior RNA extraction process. Swab specimens are inserted directly into our 1X iAMP COVID-19 Sample Buffer Mix with a 15 min incubation at room temperature and can be directly used for OMEGA isothermal amplification and signal detection. Sample to result takes less than 1.5 hours.

Primers and probes are designed to detect nucleic acid sequences from the nucleocapsid (N) gene and the ORF-1ab gene (one target sequence for each gene). Both genes are
detected within the same reaction vessel in the FAM channel without being differentiated. Primers and probes targeting the human Gapdh gene are also used on each sample as an internal control, and amplification signal is detected in HEX channel.

Both reverse transcription and nucleic acid amplification take place at 61°C. Target sequence in the specimens is amplified with N/ORF-1ab primer sets that are specific to SARS-CoV-2. During the amplification, fluorescence resonance energy transfer (FRET) probes can be incorporated in the amplification products. Upon the incorporation, fluorescence is generated and can be monitored by the fluorescence reader in a real time fashion.

**TEST WORKFLOW OVERVIEW**

![Test workflow diagram](image)

**Figure 1. Test workflow.**

**KIT COMPONENTS (100 Reactions)**

1. Primer Mix (COVIDPM) 540 µL X 1 tube
2. Buffer Mix (COVIDBM) 540 µL X 1 tube
3. Positive Control Template (COVIDPC) 300 µL X 1 tube
4. Negative Control Template (COVIDNC) 300 µL X 1 tube
5. Atila Sample Collection Device (COVID-SCD) 100 units
   - Synthetic fiber swabs with plastic shafts (100 individually packed swabs for each kit)
   - Collection tubes (100 tubes for each kit)
   - 6X Atila COVID-19 Sample Buffer A (COVID-6XSBA, 1.2 mL X 5 tubes enclosed in the kit)
   - 30X Atila COVID-19 Sample Buffer B (COVID-30XSBB, 240 µL x 5 tubes enclosed in the kit).
EQUIPMENTS & MATERIALS REQUIRED BUT NOT SUPPLIED with the kit

1. Water: nuclease-free H₂O (ThermoFisher 10977015, or equivalent)
3. PCR strips (MicroAmp™ Fast Reaction tubes, ABI, 4358293)
4. PCR cap strips (MicroAmp™ Optical 8-Cap Strips, ABI, 4323032)
5. PCR plates (Multiplate™ 96-Well PCR Plates, high profile, unskirted, clear; Biorad, MLP9601)
6. PCR Plate Sealing Film (Microseal 'B' PCR Plate Sealing Film, adhesive, optical; Biorad, MSB1001)
7. Vortex mixer or equivalent
8. PCR tube/plate holder
9. 1.5 mL and 2 mL microcentrifuge tubes and racks
10. Surface decontaminants
11. Adjustable pipettes with corresponding filter-plugged pipette tips
12. Disposable powder-free gloves and other personal protective equipment

KIT STORAGE INFORMATION

All kit reagents (COVIDBM, COVIDPM, COVIDNC, COVIDPC, 6X COVID-SBA, and 30X COVID-SBB) should be stored at -20°C freezer for long time storage. Shelf life of the kit is currently assigned as 1 year and the open kit stability is 6 months when kit is properly stored.

Swabs and collection tubes can be stored at room temperature until expiration date.

SPECIMENS

Biosafety Precautions
Wear appropriate personal protective equipment (e.g. gowns, gloves, eye protection) when working with clinical specimens. Specimen processing should be performed in a certified class II biological safety cabinet following biosafety level 2 or higher guidelines. For more information, refer to Interim Guidelines for Collecting, Handling, and Testing Clinical Specimens from Patients Under Investigation for COVID-19 (https://www.cdc.gov/coronavirus/2019-ncov/lab/lab-biosafety-guidelines.html).

Acceptable Specimens
Nasal Swabs, nasopharyngeal swabs and/or oropharyngeal swabs collected dry with the Atila Sample Collection Device (COVID-SCD; provided in the kit).

After sample collection, immediately insert swab into the collection tube provide with the Atila COVID-19 Sample Collection Device.

For In Vitro Diagnostic Use
Note: Standard precautions should be taken with regard to sample collection, handling, and storage prior to sample processing

Specimen Handling and Storage
- Use freshly collected specimens for optimal test performance.
- Specimens can be stored at room temperature for up to 12 hours, or -20°C for up to 2 days after collection and before sample processing.
- If a delay in sample processing is expected, store dry swab specimens at -70°C or lower. Avoid free-thaw cycles of the specimens.
- As soon as specimens are added to the 1x iAMP COVID-19 Sample Buffer Mix (i.e., called “processed specimens”) they need to be tested within 2 hours and may not be stored.

Specimen Rejection criteria
- Specimens not stored properly as instructed.
- Incomplete specimen labeling or documentation.
- Inappropriate specimen type.
- Insufficient specimen volume.

WARNING and PRECAUTIONS
- The assay is for in vitro diagnostic use under the FDA Emergency Use Authorization Only.
- Modifications to assay reagents, assay protocol, or instrumentation are not permitted, and are in violation of the product Emergency Use Authorization.
- This test is intended to be used with the Atila sample collection device provided in the kit. Testing of other samples collected with other collection devices may result in inaccurate results.
- Samples and controls should always be treated as if infectious and/or biohazardous in accordance with safe laboratory procedures.
- Follow necessary precautions when handling specimens. Use personal protective equipment (PPE) consistent with current guidelines for the handling of potentially infectious samples.
- Samples must be collected, transported, and stored using appropriate procedures and conditions.
- Reagents must be stored and handled as specified in these instructions for use. Do not use the kit after the indicated expiry date.
- Do not eat, drink, smoke, or apply cosmetic products in the work areas.
- Dispose of waste in compliance with local, state, and federal regulations.
- Laboratories within the United States and its territories are required to report all positive results to the appropriate public health authorities.
QUALITY CONTROL

Due to the sensitivity of iAMP COVID-19 reaction, these assays should be conducted using strict quality control and quality assurance procedures. Following the guidelines below will help minimize chance of false-positive or false-negative amplification.

General Considerations

- Personnel must be familiar with the protocol and equipment/instruments used.
- Maintain separate areas and dedicated equipment (e.g., pipettes, microcentrifuges) and supplies (e.g., microcentrifuge tubes, pipette tips, gowns and gloves) for assay reagent setup and handling of processed samples.
- Workflow must always be from the clean area to the dirty area.
- Wear clean disposable gowns and new powder-free gloves during assay reagent setup and handling of processed samples. Change gloves whenever contamination is suspected.
- Do not use reagents beyond their expiry dates.
- Keep reagent tubes and reactions capped as much as possible.
- Clean and decontaminate surfaces.
- Do not bring processed samples or reaction products into the assay setup area.
- Always use aerosol barrier (filter) pipette tips. Tips that are used must be sterile and free from DNases and RNases.

Assay Controls

Assay controls should be tested concurrently with all test samples in each instrumental run.

- PC - positive template control with an expected Ct value range, serves as a control for amplification and detection of SARS-CoV-2 RNA.
- NC - negative template control, serves to verify that analyte contamination does not occur during reaction setup.

TEST PROCEDURE

Specimen Processing

1. From the iAMP COVID-19 Detection Kit, take 6X iAMP COVID-19 Sample Buffer A (COVID-6XSBA, white cap) and 30X iAMP COVID-19 Sample Buffer B (COVID-30XSBB, purple cap) out. Each tube contains enough volume to process 20 dry swabs. Only thaw the number of COVID-6XSBA and COVID-30XSBB tubes that will be enough for each round of sample processing.

2. Make 1X iAMP COVID-19 Sample Buffer Mix by mixing (60 x N)µL COVID-6XSBA and (12 x N)µL COVID-30XSBB with (288 x N)µL nuclease-free H2O (N represents the number of dry swab specimens to be processed in one run).

3. Load 350 µL 1X iAMP COVID-19 Sample Buffer Mix into each sample tube (Atila Sample Collection Tube with the tested swab inside). Seal the tube cap securely and vortex briefly.

For In Vitro Diagnostic Use
4. Place the sample tube on the bench for 15 min.

**Note:** Make sure to use freshly prepared 1X Sample Buffer Mix for dry swab sample processing.

**Reaction assembly:**
1. Prepare iAMP COVID-19 master mix by adding \([5.2 \times (N+2)]\mu L\) PM (yellow cap) and \([5.2 \times (N+2)]\mu L\) BM (red cap) in a 1.5 mL centrifuge tube, gently vortex and spin; \(N\) represents number of specimen samples to be tested.

2. Take \(N+2\) PCR tubes (MicroAmp Fast Reaction tubes or Multiplate 96-Well PCR Plates) and add 10µL iAMP COVID-19 master mix to the bottom of each of the PCR tubes.

3. Briefly spin the tubes to bring down the liquid to the bottom of the tubes. Add 15 µL of processed specimen samples (Sample #1 to #\(N\)) from step of “Specimen Processing” to corresponding reaction PCR tubes from above Step 1. For the negative control, add 15 µL of Negative Control (blue cap) into reaction tube #\((N+1)\). For the positive control, add 15 µL of Positive Control Template (pink cap) into reaction tube #\((N+2)\).

4. Cap all the tubes securely (if using Multiplate 96-Well PCR Plates, seal the plate using Microseal ‘B’ PCR Plate Sealing Film). Gently vortex the tubes to mix all the reagents.

5. Briefly spin the tubes in a centrifuge to bring down all the liquid to the bottom of the wells.

**Run setup using Biorad CFX96 Manager Software (3.0 or higher) connected to the Biorad CFX96 Real-Time PCR System:**
1. Open the Biorad CFX Manager, and program the following setting:

<table>
<thead>
<tr>
<th>Step</th>
<th>Cycle</th>
<th>Temperature</th>
<th>Time</th>
</tr>
</thead>
<tbody>
<tr>
<td>Denaturation</td>
<td>1</td>
<td>61 °C</td>
<td>30 sec</td>
</tr>
<tr>
<td>cDNA synthesis, isothermal amplification, and signal detection</td>
<td>50</td>
<td>61 °C</td>
<td>1 min</td>
</tr>
</tbody>
</table>

Fluorescence reading is taken at the FAM/HEX channels at the end of each cycle using the default instrument settings of the Biorad CFX96 instrument.
Figure 2. Program set-up using Biorad CFX Manager.

Figure 3. Selection of fluorophores and typing NC, PC, and sample ID using Plate Editor in Biorad CFX Manager.

2. Put the reaction tubes into the sample holder in the real-time PCR machine, and make sure that the tubes are placed according to the Plate Editor setup. Then close the lid, and start the reaction run.

3. After the run, take out the sample tubes/plate and discard them immediately. To avoid contamination DO NOT OPEN THE REACTION TUBE AFTER THE REACTION and do not bring tubes in the sample processing area.

AMPLIFICATION RESULT INTERPRETATION

All test controls should be examined prior to interpretation of patient results. If the controls are not valid, the patient results cannot be interpreted.

iAMP COVID-19 Detection Kit Controls – Positive, Negative

a) Negative Control Template - serves to verify that analyte contamination does
not occur during reaction setup and is used once in each instrument run. There should be NO exponential amplification curve shown in any channel (FAM or HEX) for the negative control template, otherwise the test is invalid, and the results cannot be used for diagnosis.

b) **Positive Control Template** - serves as a control for amplification and detection of SARS-CoV-2 RNA specific sequences of the N and ORF1ab genes. It should show exponential curves in both channels (FAM and HEX), and Ct in each channel should be less than 30. If amplification is not detected within 30 Ct the test is invalid, and the results cannot be used for diagnosis.

**Examination and Interpretation of Patient Specimen Results:**
Assessment of clinical specimen test results should be performed after the positive and negative controls have been examined and determined to be valid and acceptable. If the controls are not valid, the patient results cannot be interpreted.

- **Expected Results of the Internal Control in each specimen** – The internal control serves as a nucleic acid extraction procedural control that validates both the sufficiency of sample collection as well as nucleic extraction procedure and reagent integrity. This control is a human gene present in every test sample, that is amplified with a specific primers and probe set in the kit and measured in the HEX channel. If a sample shows no exponential amplification curve in the HEX channel but an exponential curve in the FAM channel, the sample is still reported as a valid run and will be interpreted following instructions as below. If there is no exponential amplification curve in any channel in a sample, the sample test result is invalid, and a new sample of the patient needs to be collected, processed and re-tested.

- **Sample test result interpretation** - an exponential amplification curve showing up at any of the two channels (FAM/HEX) and crossing the background threshold indicates the presence of corresponding analyte as indicated below:

<table>
<thead>
<tr>
<th>FAM (ORF1ab and/or N)</th>
<th>HEX (Internal Control)</th>
<th>RESULT</th>
<th>ACTION</th>
</tr>
</thead>
<tbody>
<tr>
<td>-</td>
<td>-</td>
<td>Invalid</td>
<td>Repeat test. If result remains invalid, re-sampling is needed</td>
</tr>
<tr>
<td>-</td>
<td>+</td>
<td>SARS-CoV-2 not detected</td>
<td>Report results to healthcare provider. Consider test for other viruses that cause similar symptoms</td>
</tr>
<tr>
<td>+</td>
<td>+/-</td>
<td>SARS-CoV-2 positive</td>
<td>Report results to healthcare provider and appropriate public health authorities</td>
</tr>
</tbody>
</table>
LIMITATIONS

- The use of this assay is limited to laboratories that are certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA), 42 U.S.C. § 263a, to perform high complexity tests.
- Performance of the iAMP COVID-19 Detection Kit was established for OP and NP swab specimens only. Other specimen types have not been evaluated.
- Nasal swabs and mid-turbinate swabs are considered acceptable specimen types for use with the iAMP COVID-19 Detection Kit but performance with these specimen types has not been established. Testing of nasal and mid-turbinate nasal swabs (self-collected under supervision of or collected by a healthcare provider) is limited to patients with symptoms of COVID-19. Please refer to FDA’s FAQs on Diagnostic testing for SARS-CoV-2 for additional information.
- Improper collection, transport, or storage of specimens may impact the ability of the assay to perform as indicated.
- False-negative results may arise from: Improper sample collection, storage and transport and resulting in degradation of the SARS-CoV-2 RNA, the presence of RT-PCR inhibitors, Mutation in the SARS-CoV-2 virus, and/or failure to follow instructions for use.
- The impacts of vaccines, antiviral therapeutics, antibiotics, chemotherapeutic or immunosuppressant drugs have not been evaluated.
- The iAMP COVID-19 Detection Kit cannot rule out respiratory diseases caused by other bacterial or viral pathogens.
- Negative results do not preclude infection with SARS-CoV-2 virus and should not be the sole basis of a patient management decision.
- Laboratories are required to report results consistent with local, state and federal public health authorities.

CONDITIONS OF AUTHORIZATION FOR THE LABORATORY

The iAMP COVID-19 Detection Kit Letter of Authorization, along with the authorized Fact Sheet for Healthcare Providers, the authorized Fact Sheet for Patients, and authorized labeling are available on the FDA website: https://www.fda.gov/medical-devices/emergency-situations-medical-devices/emergency-use-authorizations#covid19ivd.

However, to assist clinical laboratories using the iAMP COVID-19 Detection Kit (“your product” in the conditions below), the relevant Conditions of Authorization are listed below:

- Authorized laboratories1 using your product will include with result reports of your product, all authorized Fact Sheets. Under exigent circumstances, other appropriate methods for disseminating these Fact Sheets may be used, which may include mass media.
- Authorized laboratories using your product will use your product as outlined in the Instructions for Use. Deviations from the authorized procedures, including the authorized instruments, authorized extraction methods, authorized clinical specimen types, authorized control materials, authorized other ancillary reagents and authorized materials required to use your product are not permitted.
- Authorized laboratories that receive your product will notify the relevant public health authorities of their intent to run your product prior to initiating testing.
- Authorized laboratories using your product will have a process in place for reporting test results to healthcare providers and relevant public health authorities, as appropriate.
- Authorized laboratories will collect information on the performance of your product and report to DMD/OHT7-OIR/OPEQ/CDRH (via email: CDRH-EUA-Reporting@fda.hhs.gov) and Atila
For In Vitro Diagnostic Use

BioSystems, Inc. (Covid19_support@atilabiosystems.com) any suspected occurrence of false positive or false negative results and significant deviations from the established performance characteristics of your product of which they become aware.

- All laboratory personnel using your product must be appropriately trained in real-time nucleic acid amplification techniques and use appropriate laboratory and personal protective equipment when handling this kit, and use your product in accordance with the authorized labeling.

- Atila BioSystems, Inc., authorized distributors, and authorized laboratories using your product will ensure that any records associated with this EUA are maintained until otherwise notified by FDA. Such records will be made available to FDA for inspection upon request.

1 The letter of authorization refers to, “laboratories certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA), 42 U.S.C. §263a, to perform high complexity tests” as “authorized laboratories.”

PERFORMANCE CHARACTERISTICS

Limit of Detection (LoD) – Analytical Sensitivity

The analytical sensitivity of iAMP COVID-19 Detection Kit was determined in Limit of Detection (LoD) studies using Biorad CFX96 Real-Time System. The iAMP COVID-19 Detection Kit were tested according to the Instructions for Use using SARS-CoV-2 RNA (Twist Biosciences) for a tentative LoD study. Oropharyngeal swab collected from healthy individuals were treated with 1x iAMP COVID-19 Sample Buffer Mix. Negative samples were tested by iAMP COVID-19 Detection Kit and confirmed to be negative. Known titer of Twist SARS-CoV-2 RNA was then spiked into the negative oropharyngeal swab specimens to mimic clinical samples and the contrived samples were processed following the IFU of iAMP COVID-19 Detection Kit. The tentative LoD of the assay was determined for swab matrix.

Due to the competition in the multiplex assay, amplification of SARS-COV-2 target may delay or totally suppress the internal control signal. Therefore, samples with a positive fluorescence signal for the ORF1ab/N targets are valid positive even in the absence of the internal control.

<table>
<thead>
<tr>
<th>Target Level</th>
<th>Valid results</th>
<th>SARS-CoV-2 (N/ORF) Positive n</th>
<th>Mean Ct</th>
<th>SARS-CoV-2 (N/ORF) Detection Rate</th>
<th>Internal Control Positive n</th>
<th>Mean Ct</th>
<th>Internal control Detection Rate</th>
</tr>
</thead>
<tbody>
<tr>
<td>0.4 cp/μL</td>
<td>5</td>
<td>4</td>
<td>18.55</td>
<td>80%</td>
<td>5</td>
<td>24.73</td>
<td>100%</td>
</tr>
</tbody>
</table>
A confirmatory LoD study for Biorad CFX96 Real-Time System was performed using AccuPlex SARS-CoV-2 Verification Panel from SeraCare (0505-0129). Pseudovirus was spiked into negative oropharyngeal swab specimen at the concentration of 4 copies/µL sample and processed following the IFU of the iAMP COVID-19 Detection Kit.

<table>
<thead>
<tr>
<th>Target Level</th>
<th>Valid results</th>
<th>SARS-CoV-2 (N/ORF)</th>
<th>SARS-CoV-2 (N/ORF)</th>
<th>Internal Control</th>
<th>Internal Control</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>n</td>
<td>Positive</td>
<td>Detection Rate</td>
<td>Positive</td>
<td>Detection Rate</td>
</tr>
<tr>
<td>4 cp/µL</td>
<td>20</td>
<td>20</td>
<td>16.87</td>
<td>14</td>
<td>25.77</td>
</tr>
</tbody>
</table>

20 Replicates were tested and positive results were obtained in all 20 replicates. Therefore, the LoD of iAMP COVID-19 Detection Kit is 4 copies/µL sample for the Biorad CFX96 Real-Time System.

Inclusivity
All primer-annealing regions in both Orf1ab and N were analyzed in silico using nBLAST, and showed 100% match to all of the published SARS-CoV-2 complete genome sequences from Genbank (n=154 as of March 21, 2020). The iAMP COVID-19 kit is therefore predicted to detect all currently circulating strains for SARS-CoV-2.

Cross-Reactivity (Analytical Specificity)
The list of organisms shown below has been analyzed in silico for potential cross-reactivity with the primers or probe sequences in the iAMP COVID-19 test. There were no primers and probes in the iAMP COVID-19 Detection Kit with homology ≥ 80% and therefore cross reactivity with the organisms below is not expected.

For In Vitro Diagnostic Use
### Organisms tested in in Silico Cross-Reactivity analysis

<table>
<thead>
<tr>
<th>Pathogen</th>
<th>GenBank Acc#</th>
<th>Pathogen</th>
<th>GenBank Acc#</th>
</tr>
</thead>
<tbody>
<tr>
<td>Human coronavirus 229E</td>
<td>NC_002645.1</td>
<td>Parainfluenza virus 4a isolate HPIV4_DK(459)</td>
<td>KF483663.1</td>
</tr>
<tr>
<td>Human coronavirus OC43</td>
<td>NC_006213.1</td>
<td>Parainfluenza virus 4b strain 04-13</td>
<td>JQ241176.1</td>
</tr>
<tr>
<td>Human coronavirus HKU1</td>
<td>NC_006577.2</td>
<td>Influenza B B/Illinois/13/2005 (segment 7)</td>
<td>CY019500.1</td>
</tr>
<tr>
<td>Human coronavirus NL63</td>
<td>NC_005831.2</td>
<td>Enterovirus 68 isolate NZ-2010-541</td>
<td>JX070222.1</td>
</tr>
<tr>
<td>SARS-coronavirus B093</td>
<td>AY686864</td>
<td>Respiratory syncytial virus</td>
<td>NC_001803</td>
</tr>
<tr>
<td>MERS-coronavirus NL140422</td>
<td>MG021452.1</td>
<td>Human Rhinovirus B3 strain SC2606</td>
<td>KY967365.1</td>
</tr>
<tr>
<td>Human Metapneumovirus (hMPV) isolate 00-1</td>
<td>NC_039199</td>
<td>Chlamydia pneumoniae TW-183</td>
<td>NC_005043.1</td>
</tr>
<tr>
<td>Parainfluenza virus 1 isolate NM001</td>
<td>KX639498.1</td>
<td>Bordetella pertussis strain B3921</td>
<td>CP011448.1</td>
</tr>
<tr>
<td>Parainfluenza virus 2 isolate VIROAF10</td>
<td>KM190939.1</td>
<td>Pseudomonas aeruginosa UCBPP-PA14</td>
<td>CP000438.1</td>
</tr>
<tr>
<td>Parainfluenza virus 3 strain HPIV3/AUS/3/2007</td>
<td>KF530243.1</td>
<td>Streptococcus salivarius CCHSS3</td>
<td>FR873481.1</td>
</tr>
</tbody>
</table>

In addition, the organisms listed in the table below were wet-tested. Oropharyngeal swab collected from healthy individuals were treated with 1x iAMP COVID-19 Sample Buffer Mix. Then purified genome DNA/RNA spiked into the negative oropharyngeal swab specimen at the concentration of 10^5 genome copies/µL sample. Samples were processed following the IFU. Three replicates were tested for each organism. No false positive signal was observed in FAM channel (which SARS-CoV-2 is assigned) for any of the replicates when testing with the iAMP COVID-19 Detection Kit, whereas amplification
curves for the internal control in the HEX channel showed up as expected. No cross reactivity was observed with the organisms below at the tested concentration.

<table>
<thead>
<tr>
<th>Organisms wet-tested in swab matrix</th>
<th>SARS-CoV-2 (N/ORF) Detection Rate</th>
</tr>
</thead>
<tbody>
<tr>
<td>Adenovirus (ATCC VR-1516)</td>
<td>0% (0/3)</td>
</tr>
<tr>
<td>Influenza A (H1N1)</td>
<td>0% (0/3)</td>
</tr>
<tr>
<td><em>Haemophilus influenzae</em></td>
<td>0% (0/3)</td>
</tr>
<tr>
<td><em>Legionella pneumophila</em></td>
<td>0% (0/3)</td>
</tr>
<tr>
<td><em>Mycobacterium tuberculosis</em></td>
<td>0% (0/3)</td>
</tr>
<tr>
<td><em>Streptococcus pneumoniae</em></td>
<td>0% (0/3)</td>
</tr>
<tr>
<td><em>Streptococcus pyogenes</em></td>
<td>0% (0/3)</td>
</tr>
<tr>
<td><em>Mycoplasma pneumoniae</em></td>
<td>0% (0/3)</td>
</tr>
<tr>
<td><em>Pneumocystis jirovecii</em> (PJP)</td>
<td>0% (0/3)</td>
</tr>
<tr>
<td><em>Candida albicans</em></td>
<td>0% (0/3)</td>
</tr>
</tbody>
</table>

**Endogenous Interference Substances Studies:**

Interfering substances studies were performed for iAMP COVID-19 Detection Kit. Oropharyngeal swab collected from healthy individuals were treated with 1x iAMP COVID-19 Sample Buffer Mix. Then Synthetic SARS-CoV-2 RNA (Twist BioSciences) was spiked into the negative oropharyngeal swab specimens at the concentration of 2.5X LoD (10 copies/µL sample). The potentially interfering substances indicated in the table below were added to the positive contrived samples at the indicated concentration, and the samples were processed following IFU. Each substance was also added to the negative oropharyngeal swab specimen to test potential false positives. Each substance was tested in three replicates for positive contrived samples and three replicates for negative swab specimens. Results indicate that iAMP COVID-19 can well tolerate all the substances at the concentration equal or lower than the indicated values without significant interference. Neither false positive or false negative was observed.

<table>
<thead>
<tr>
<th>Potential Interfering Substance</th>
<th>Conc.</th>
<th>Positive Samples</th>
<th>Negative Samples</th>
</tr>
</thead>
</table>

For *In Vitro* Diagnostic Use
| Mucin: bovine submaxillary gland, type I-S | 2.5 mg/ml | 2.5X LoD | 3/3 | 0/3 |
| Blood (human) | 2.5% v/v | 2.5X LoD | 3/3 | 0/3 |
| Afrin Original nasal spray | 15% v/v | 2.5X LoD | 3/3 | 0/3 |
| Basic Care allergy relief nasal spray (Gluocorticoid) | 5% v/v | 2.5X LoD | 3/3 | 0/3 |
| NeilMed Nasal gel | 1.25% | 2.5X LoD | 3/3 | 0/3 |
| GoodSense All Day Allergy, Cetirizine HCl Tablets 10 mg | 1mg/mL | 2.5X LoD | 3/3 | 0/3 |
| Cepacol Sore Throat (benzocaine/menthol lozenges) | 5 mg/mL | 2.5X LoD | 3/3 | 0/3 |
| Zanamivir | 3.3 mg/mL | 2.5X LoD | 3/3 | 0/3 |
| Tamiflu | 2.2 µg/mL | 2.5X LoD | 3/3 | 0/3 |
| Mupirocin ointment | 5mg/mL | 2.5X LoD | 3/3 | 0/3 |
| Tobramycin | 4ug/mL | 2.5X LoD | 3/3 | 0/3 |

**Clinical Evaluation**

Clinical performance evaluation for the iAMP COVID-19 Detection Kit was performed using the AccuPlex SARS-CoV-2 Verification Panel from SeraCare (0505-0129) and the Biorad CFX96 Real-Time System. Oropharyngeal swab collected from healthy individuals were treated with 1x iAMP COVID-19 Sample Buffer Mix. Pseudovirus was spiked into the first aliquot of negative oropharyngeal swab specimen so that positive contrived samples were generated at the concentration of 8 copies/µL sample (2X LoD; 20 samples), 20 copies/µL sample (5X LoD; 10 samples), and 40 copies/µL sample (10X LoD; 5 samples). In addition, the second aliquot of the negative oropharyngeal swabs was spiked with negative control material provided by Seracare. All samples were processed following IFU of the kit.
<table>
<thead>
<tr>
<th>Target Level</th>
<th>Valid results</th>
<th>SARS-CoV-2 (N/ORF) Positive</th>
<th>SARS-CoV-2 (N/ORF) Detection Rate</th>
<th>Internal Control Positive</th>
<th>Internal Control Detection Rate</th>
</tr>
</thead>
<tbody>
<tr>
<td>Negative</td>
<td>40</td>
<td>40 NA</td>
<td>0%</td>
<td>40 22.9</td>
<td>100%</td>
</tr>
<tr>
<td>2 X LoD</td>
<td>20</td>
<td>20 15.22</td>
<td>100%</td>
<td>19 26.3</td>
<td>95%</td>
</tr>
<tr>
<td>5 X LoD</td>
<td>10</td>
<td>10 14.07</td>
<td>100%</td>
<td>5 25.42</td>
<td>50%</td>
</tr>
<tr>
<td>10 X LoD</td>
<td>5</td>
<td>5 13.07</td>
<td>100%</td>
<td>0 NA</td>
<td>0%</td>
</tr>
</tbody>
</table>